Results 201 to 210 of about 2,023,116 (304)

Engineering Resatorvid‐Loaded Sub‐Microgels of Epigallocatechin‐3‐gallate/Hyaluronic Acid to Treat Acute Lung Injury

Advanced Healthcare Materials, EarlyView.
This study presents HAEP@Res sub‐microgels as a lung‐targeted delivery system integrating antioxidant activity with anti‐inflammatory therapy. The sub‐microgels demonstrate excellent biocompatibility, efficiently scavenge intracellular ROS, and downregulate pro‐inflammatory cytokines and genes in a Bleo‐induced ALI mouse model. These findings highlight
Bo Liu, Olawale Alimi Alimi, Benjamin Stearnes, Svetlana Romanova, Brady J. Sillman, Mena Asha Krishnan, Kristina Bailey, Benson J. Edagwa, Huanhuan Joyce Chen, Han‐jun Wang, Bin Duan   +10 more
wiley   +1 more source

Myokine SIRPα exacerbates kidney disease in diabetes. [PDF]

JCI Insight
Wu J, Russo E, Verzola D, Li Q, Zhang H, Krishnan B, Sheikh-Hamad D, Hu Z, Mitch WE, Thomas SS.   +9 more
europepmc   +1 more source

Shellac‐Mediated Assembly of Nanoparticles for mRNA Delivery

Advanced Healthcare Materials, EarlyView.
A shellac‐mediated nanoparticle assembly strategy is presented, involving the complexation of mRNA and low‐molecular‐weight cationic molecules (e.g., polyethyleneimine, chitosan, lipids, and poly‐l‐lysine), followed by capping with shellac. This nanoparticle platform enables mRNA transfection following intravenous injection and facilitates gene editing
Meizhang Lu, Jingqu Chen, Zhixing Lin, Wanjun Xu, Tianzheng Wang, Shiyao Li, Die Yang, Frank Caruso   +7 more
wiley   +1 more source

Framework for Apolipoprotein 1-Mediated Kidney Disease Classification. [PDF]

Kidney Int Rep
Wilson JD, Caza TN, Haun RS, Larsen CP.
europepmc   +1 more source

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

Advanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen, Neona M. Lowe, Sophia Kellogg, Kuan‐Wei Huang, Hannah O'Toole, Elizabeth J. Hale, Venktesh S. Shirure, Bhupinder S. Shergill, Steven C. George, Randy P. Carney   +9 more
wiley   +1 more source

WCN24-1086 THE EFFICIENCY AND SAFETY OF OBINUTUZUMAB IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY-A RETROSPECTIVE STUDY FROM CHINA

Kidney International Reports
Chen Duqun, Tu Yuanmao, Wang Youliang, Qiu Dandan, Wang Jingjing, Zuo Ke, Cheng Zhen   +6 more
doaj   +1 more source

Research progress in single‑cell omics technologies for kidney disease (Review). [PDF]

Int J Mol Med
Xu J, Chen Z, Li S, Wang X, Chen M.
europepmc   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source

A Study of Intradialytic Complications in Chronic Kidney Disease Patients. [PDF]

Cureus
Nilugal B, Biradar SM, Patil S.
europepmc   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

Advanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa, Gracia Mendoza, Silvia Irusta, Manuel Arruebo   +3 more
wiley   +1 more source